Skip to main content
SpringerLink
Log in

Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT

  • Original article
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

Abstract

Purpose

The iodinated cocaine derivative [123I]PE2I is a new selective ligand for in vivo studies of the dopamine transporter (DAT) with SPECT. Recently, a bolus/infusion (B/I) protocol for [123I]PE2I measurements of DAT density was established [Pinborg LH et al. J Nucl Med 2005;46:1119–271]. The aims of this study were, firstly, to evaluate the test–retest variability using the B/I protocol and, secondly, to evaluate the B/I approach in a new group of healthy subjects using two outcome parameters, BP1 (CROI/Cplasma) and BP2 (CROI/CREF).

Methods

Seven healthy subjects were subjected to [123I]PE2I SPECT scanning twice. For both studies, the two outcome parameters BP1 and BP2 were calculated based on two different methods for region of interest (ROI) delineation, namely manual delineation and probability map-based automatic delineation with MRI co-registration.

Results

With manual delineation, striatal test–retest variability (absolute difference between first and second scan as a percentage of the mean) of BP1 and BP2 was 13.9% (range 1.8–35.7%) and 4.1% (range 0.5–9.7%) respectively. The probability map-based automatic delineation resulted in striatal test–retest variability of 17.2% (range 4.3–40.5%) and 5.2% (range 0.1–10.9%) respectively. The B/I approach provided stable brain activity from 120 to 180 min post injection in both high- and low-count regions with a mean % change/hour in striatal BP2 of 10.6.

Conclusion

[123I]PE2I SPECT with the B/I approach yields a highly reproducible measure of striatal dopamine transporter binding. The appropriateness of a B/I protocol with a B/I ratio of 2.7 h (i.e. with a bolus worth 2.7 h of infusion) was confirmed in an independent sample of healthy subjects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Pinborg LH, Ziebell M, Frokjaer VG, de Nijs R, Svarer C, Haugbol S, et al. Quantification of 123I-PE2I binding to dopamine transporter with SPECT after bolus and bolus/infusion. J Nucl Med 2005;46(7):1119–1127

    PubMed  Google Scholar 

  2. Allard PO, Rinne J, Marcusson JO. Dopamine uptake sites in Parkinson’s disease and in dementia of the Alzheimer type. Brain Res 1994;637(1–2):262–266

    Article  PubMed  CAS  Google Scholar 

  3. Bao SY, Wu JC, Luo WF, Fang P, Liu ZL, Tang J. Imaging of dopamine transporters with technetium-99m TRODAT-1 and single photon emission computed tomography. J Neuroimaging 2000;10(4):200–203

    PubMed  CAS  Google Scholar 

  4. Brucke T, Asenbaum S, Pirker W, Djamshidian S, Wenger S, Wober C, et al. Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl 1997;50:9–24

    PubMed  CAS  Google Scholar 

  5. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci USA 1993;90(24):11965–11969

    Article  PubMed  CAS  Google Scholar 

  6. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson’s disease. Ann Neurol 2000;47(4):493–503

    Article  PubMed  CAS  Google Scholar 

  7. Marshall V, Grosset DG. Role of dopamine transporter imaging in the diagnosis of atypical tremor disorders. Mov Disord 2003;18(Suppl 7):S22–S27

    Article  PubMed  Google Scholar 

  8. Prunier C, Bezard E, Montharu J, Mantzarides M, Besnard JC, Baulieu JL, et al. Presymptomatic diagnosis of experimental parkinsonism with 123I-PE2I SPECT. Neuroimage 2003;19(3):810–816

    Article  PubMed  Google Scholar 

  9. Knudsen GM, Karlsborg M, Thomsen G, Krabbe K, Regeur L, Nygaard T, et al. Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2004;31(12):1631–1638

    Article  PubMed  CAS  Google Scholar 

  10. Varrone A, Marek KL, Jennings D, Innis RB, Seibyl JP. [123I]beta-CIT SPECT imaging demonstrates reduced density of striatal dopamine transporters in Parkinson’s disease and multiple system atrophy. Mov Disord 2001;16(6):1023–1032

    Article  PubMed  CAS  Google Scholar 

  11. Carroll FI, Rahman MA, Philip A, Lewin AH, Boja JW, Kuhar MJ. Synthesis and receptor binding of cocaine analogs. NIDA Res Monogr 1991;105:147–153

    Google Scholar 

  12. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2beta-carbomethoxy-3beta-(4′-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2beta-carbomethoxy-3beta-(3′,4′-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 1997;40(9):1366–1372

    Article  PubMed  CAS  Google Scholar 

  13. Videbaek C, Knudsen GM, Bergstrom KA, Hiltunen J, Pinborg LH, Kuikka JT, et al. Octanol extraction yields similar results as HPLC for quantification of [123I]PE2I metabolism. Eur J Nucl Med 1999;26:1139

    Google Scholar 

  14. Kretschmann H-J, Weinrich W. Neuroanatomy and cranial computed tomography. Stuttgart: Thieme; 1986

    Google Scholar 

  15. Svarer C, Madsen K, Hasselbalch SG, Pinborg LH, Haugbol S, Frokjaer VG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. Neuroimage 2005;24(4):969–979

    Article  PubMed  Google Scholar 

  16. Ashburner J, Friston K. Multimodal image coregistration and partitioning—a unified framework. Neuroimage 1997;6(3):209–217

    Article  PubMed  CAS  Google Scholar 

  17. Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992;16(4):620–633

    Article  PubMed  CAS  Google Scholar 

  18. Pietrzyk U, Herholz K, Fink G, Jacobs A, Mielke R, Slansky I, et al. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 1994;35(12):2011–2018

    PubMed  CAS  Google Scholar 

  19. Booij J, Habraken JB, Bergmans P, Tissingh G, Winogrodzka A, Wolters EC, et al. Imaging of dopamine transporters with iodine-123-FP-CIT SPECT in healthy controls and patients with Parkinson’s disease. J Nucl Med 1998;39(11):1879–1884

    PubMed  CAS  Google Scholar 

  20. Morrish PK. How valid is dopamine transporter imaging as a surrogate marker in research trials in Parkinson’s disease? Mov Disord 2003;18(Suppl 7):S63–S70

    Article  PubMed  Google Scholar 

  21. Pirker W, Djamshidian S, Asenbaum S, Gerschlager W, Tribl G, Hoffmann M, et al. Progression of dopaminergic degeneration in Parkinson’s disease and atypical parkinsonism: a longitudinal beta-CIT SPECT study. Mov Disord 2002;17(1):45–53

    Article  PubMed  Google Scholar 

  22. Seibyl JP, Marek K, Sheff K, Baldwin RM, Zoghbi S, Zea-Ponce Y, et al. Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson’s patients. J Nucl Med 1997;38(9):1453–1459

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank Karin Stahr for expert technical assistance. This work was supported by the Danish Medical Research Council, the Toyota Foundation, the Elsass Foundation, the University of Copenhagen and H:S Hovedstadens Sygehusfællesskab.

Author information

Authors and Affiliations

  1. Neurobiology Research Unit, Rigshospitalet, N9201, 9 Blegdamsvej, Copenhagen, 2100, Denmark

    Morten Ziebell, Gerda Thomsen, Gitte M. Knudsen, Robin de Nijs, Claus Svarer & Lars H. Pinborg

  2. Diagnostic Radiology, University Hospital Rigshospitalet, Copenhagen, Denmark

    Aase Wagner

Authors
  1. Morten Ziebell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gerda Thomsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gitte M. Knudsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robin de Nijs
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Claus Svarer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Aase Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lars H. Pinborg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Morten Ziebell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ziebell, M., Thomsen, G., Knudsen, G.M. et al. Reproducibility of [123I]PE2I binding to dopamine transporters with SPECT. Eur J Nucl Med Mol Imaging 34, 101–109 (2007). https://doi.org/10.1007/s00259-006-0161-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-006-0161-z

Keywords

Search

Navigation